Offer may change at any time, without notice
The caloric deficit that semaglutide helped create at your starting weight becomes insufficient at your new, lower weight
Semaglutide suppresses glucagon secretion, reducing the liver's glucose production and preventing blood sugar spikes
Ongoing trials by Novo Nordisk aim to explore the link between semaglutide use and diabetic retinopathy, with results expected by 2027
By reducing these spikes, semaglutide can help maintain a more stable blood sugar level, even in the presence of high cortisol
Retatrutide TRIUMPH-1 (2023) and TRIUMPH-2 (2024) TRIUMPH-1 (Jastreboff et al., NEJM 2023): 338 non-diabetic adults with obesity, 48 weeks at escalating doses: 12 mg dose: 24.2% weight loss 8 mg dose: 22.8% 4 mg dose: 17.5% Placebo: 2.1% TRIUMPH-2 (Rosenstock et al., Lancet 2024) confirmed effects in T2D patients with concurrent NAFLD improvement (hepatic fat reduction 54% at 24 weeks, 12 mg dose)